This study was motivated by the need to provide more insight into the possible mechanism of the intermolecular interactions between antispasmodic drug drotaverine and one of the serum albumins (BSA), with the aim to indicate the most probable sites of these interactions. For this purpose both experimental (spectrofluorometric titration at various temperatures) and theoretical (molecular mechanics) methods have been applied. The obtained results clearly showed that drotaverine quenched BSA fluorescence, and the most probable mechanism is static quenching. The negative value of the theoretically predicted binding free Gibbs energy (-23.8 kJ/mol) confirmed the existence of the intermolecular interactions involving drotaverine and one tryptophan within BSA protein and was well agreed with the experimentally determined value of -25.2 kJ/mol.
2
Dostęp do pełnego tekstu na zewnętrznej witrynie WWW
A simple, rapid reversed-phase high-performance liquid chromatographic method has been developed and validated for simultaneous estimation of drotaverine and omeprazole in a tablet dosage form. A C 18 column was used with a 60:40 ( v/v ) mixture of methanol and ammonium acetate (0.1 M , pH 5, adjusted with orthophosphoric acid) as mobile phase at a flow rate of 1.5 mL min -1 . UV detection was performed at 319 nm. The method was validated for accuracy, precision, linearity, specificity and sensitivity in accordance with International Conference on Harmonisation guidelines. The method was successfully used for quantitative analysis of Ranipas-DV tablets. Total run time was 10 min, drotaverine and omeprazole were eluted with retention times of 7.969 and 6.538 min respectively. Validation revealed that the method is specific, accurate, precise, reliable and reproducible. Calibration plots were linear over the concentration ranges 5-40 µg mL -1 for drotaverine and 5-50 µg mL -1 for omeprazole, respectively. Limits of detection were 16.2 and 4.8 ng mL -1 and limits of quantification were 49.0 and 14.5 ng mL -1 for drotaverine and omeprazole, respectively. Recovery was in the range 100.66-100.94% and 102.42-102.89% for drotaverine and omeprazole, respectively, and the coefficient of variance was <2.0% for both. The high percentage recovery and low co-efficient of variation confirm the suitability of the method for simultaneous analysis of drotaverine and omeprazole in tablets.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.